Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging

The tyrosine kinase inhibitors (TKIs), including sorafenib, remain one first-line antitumor treatment strategy for advanced hepatocellular carcinoma (HCC). However, many problems exist with the current orally administered TKIs, creating a heavy medical burden and causing severe side effects. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Junxiao, Liu, Rui, Zhao, Yun, Ma, Zhenhu, Sang, Zejie, Wen, Zhenyu, Yang, Xueling, Xie, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426437/
https://www.ncbi.nlm.nih.gov/pubmed/34513717
http://dx.doi.org/10.3389/fonc.2021.743055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426437/
https://www.ncbi.nlm.nih.gov/pubmed/34513717
http://dx.doi.org/10.3389/fonc.2021.743055

Ejemplares similares